Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 12/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2031012 | 0.88 | RPS6KB1 (0.49) | RPS6KB1KDM4EL3MBTL1EGFR | |
| SCHEMBL2031010 | 0.88 | RPS6KB1 (0.49) | RPS6KB1KDM4EL3MBTL1EGFR | |
| SCHEMBL21310909 | 0.87 | RPS6KB1 (0.58) | RPS6KB1KDM4EL3MBTL1IDH1EGFR | |
| SCHEMBL21310906 | 0.87 | RPS6KB1 (0.58) | RPS6KB1KDM4EL3MBTL1IDH1EGFR | |
| SCHEMBL18477019 | 0.81 | RPS6KB1 (0.55) | RPS6KB1KDM4EL3MBTL1IDH1 | |
| SCHEMBL21311054 | 0.79 | PRKACA (0.50) | RPS6KB1KDM4EL3MBTL1EGFR | |
| SCHEMBL21310910 | 0.79 | GRK6 (0.46) | RPS6KB1KDM4EIDH1EGFRPTGER4 | |
| SCHEMBL2030741 | 0.77 | L3MBTL1 (0.57) | RPS6KB1KDM4EL3MBTL1 | |
| SCHEMBL1923774 | 0.76 | CYP11B2 (0.49) | KDM4EL3MBTL1EGFR | |
| SCHEMBL1923775 | 0.76 | CYP11B2 (0.49) | KDM4EL3MBTL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| WO-2019162323-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | RPS6KB1 357/4885KDM4E 2662/4885L3MBTL1 1629/4885 |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | EGFR, ERBB2, ERBB3 | RPS6KB1 412/4885KDM4E 2411/4885L3MBTL1 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.